Compare Ascendis Pharma A/S (ASND) vs SAP SE (SAP) Price & Performance

Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.

The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.

SAP trades at $157.86, down 0.38% on the day, amid a bearish technical signal but strong fundamental performance. The stock has beaten earnings expectations for three consecutive quarters, with Q2 2026 EPS expected at $2.05. Revenue grew to $36.80B in 2025, with a net income margin of 19.58%, while the company maintains robust cash flow from operations of $9.16B. Recent news highlights SAP's resolution of EU antitrust concerns and strategic focus on AI investments to drive future growth.

The outlook for SAP is positive based on solid fundamentals and analyst consensus, with a price target of $228.50 implying significant upside. However, risks include competitive pressures, execution of AI initiatives, and macroeconomic volatility. Investors should weigh the strong profitability and growth trajectory against near-term technical weakness and market sentiment shifts.